CO4970814A1 - Formulaciones de tiagabine de liberacion prolongada con efec tos secundarios reducidos - Google Patents

Formulaciones de tiagabine de liberacion prolongada con efec tos secundarios reducidos

Info

Publication number
CO4970814A1
CO4970814A1 CO99003109A CO99003109A CO4970814A1 CO 4970814 A1 CO4970814 A1 CO 4970814A1 CO 99003109 A CO99003109 A CO 99003109A CO 99003109 A CO99003109 A CO 99003109A CO 4970814 A1 CO4970814 A1 CO 4970814A1
Authority
CO
Colombia
Prior art keywords
weight
group
tiagabine
release formulation
prolonged release
Prior art date
Application number
CO99003109A
Other languages
English (en)
Inventor
Francisco J Alvarez
T Slade Russwll
M Apfelbaum Kathleen
David M Brown
Linda E Gustavson
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CO4970814A1 publication Critical patent/CO4970814A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulación de liberación prolongada que comprende tiagabinecombinado en una matriz con un polímero hidrofílico seleccionado del grupo conformado por un polietilenóxido de alto peso molecular e hidroxipropilmetilcelulosa. Una formulación de liberación prolongada que comprende tiagabine encapsulado dentro de una formulación con un material hidrofóbico seleccionado del grupo conformado por ceras, behenato de glicerilo, triglicéridos y mezclas de éstos. Una formulación de liberación prolongada que comprende desde 0,5 hasta 30% en peso de tiagabine combinado en una matriz que contiene: a. desde 15 hasta 80% en peso de polietilenóxido de alto peso molecular; b. desde 5 hasta 80% en peso de un material de relleno seleccionado del grupo conformado por celulosa microcristalina, almidón y azúcares; c. desde 0,1 hasta 4% en peso de dióxido de silicio; d. desde 0,1 hasta 1,5% en peso de un preservativo seleccionado del grupo conformado por tocoferol, BHA y BHT; e. desde 0,1 hasta 6% en peso de un primer lubricante seleccionado del grupo conformado por una cera, ácido esteárico, un estearato y un aceite vegetal hidrogenado; y f. desde 0,05% hasta 1% en peso de un segundo lubricante seleccionado del grupo conformado por estearato de magnesio, estearato de calcio y talco.
CO99003109A 1998-01-22 1999-01-21 Formulaciones de tiagabine de liberacion prolongada con efec tos secundarios reducidos CO4970814A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7213098P 1998-01-22 1998-01-22

Publications (1)

Publication Number Publication Date
CO4970814A1 true CO4970814A1 (es) 2000-11-07

Family

ID=22105780

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99003109A CO4970814A1 (es) 1998-01-22 1999-01-21 Formulaciones de tiagabine de liberacion prolongada con efec tos secundarios reducidos

Country Status (23)

Country Link
US (1) US20070053980A1 (es)
EP (1) EP1049470B1 (es)
JP (1) JP2002501022A (es)
KR (1) KR20010034313A (es)
CN (1) CN1145484C (es)
AR (1) AR018041A1 (es)
AT (1) ATE350035T1 (es)
AU (1) AU2239599A (es)
BG (1) BG104692A (es)
CA (1) CA2318448A1 (es)
CO (1) CO4970814A1 (es)
DE (1) DE69934670D1 (es)
HU (1) HUP0101739A3 (es)
IL (1) IL137324A0 (es)
NO (1) NO20003677L (es)
NZ (1) NZ505725A (es)
PL (1) PL194595B1 (es)
SA (1) SA99200204B1 (es)
SK (1) SK11072000A3 (es)
TR (2) TR200002102T2 (es)
TW (1) TW585787B (es)
WO (1) WO1999037302A1 (es)
ZA (1) ZA99407B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872734B2 (en) 2000-10-20 2005-03-29 Abbott Laboratories Use of tiagabine for treatment of diabetic neuropathy and migraine
KR100510270B1 (ko) * 2002-11-29 2005-08-26 센츄론(주) 펠렛타이저를 이용한 서방성 제제의 제조방법
CN102908327B (zh) * 2011-08-05 2015-03-11 江苏恒瑞医药股份有限公司 伊伐布雷定或其可药用盐的缓释制剂
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
UA43402C2 (uk) * 1995-05-05 2001-12-17 Ново Нордіск А/С Фармацевтична композиція, що містить тіагабінгідрохлорид, та спосіб її одержання
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
AU8643698A (en) * 1997-08-01 1999-02-22 Elan Corporation, Plc Controlled release pharmaceutical compositions containing tiagabine
US5843477A (en) * 1997-09-30 1998-12-01 Bayer Corporation Lubricants for use in tabletting

Also Published As

Publication number Publication date
EP1049470B1 (en) 2007-01-03
HUP0101739A3 (en) 2002-10-28
SK11072000A3 (sk) 2001-01-18
TW585787B (en) 2004-05-01
ATE350035T1 (de) 2007-01-15
TR200505223T2 (tr) 2006-04-21
KR20010034313A (ko) 2001-04-25
NO20003677L (no) 2000-09-20
BG104692A (en) 2001-05-31
AR018041A1 (es) 2001-10-31
EP1049470A1 (en) 2000-11-08
ZA99407B (en) 1999-07-20
CN1145484C (zh) 2004-04-14
NZ505725A (en) 2003-01-31
AU2239599A (en) 1999-08-09
SA99200204B1 (ar) 2006-10-11
US20070053980A1 (en) 2007-03-08
TR200002102T2 (tr) 2000-12-21
DE69934670D1 (de) 2007-02-15
PL342767A1 (en) 2001-07-02
JP2002501022A (ja) 2002-01-15
CN1293571A (zh) 2001-05-02
CA2318448A1 (en) 1999-07-29
NO20003677D0 (no) 2000-07-18
IL137324A0 (en) 2001-07-24
PL194595B1 (pl) 2007-06-29
WO1999037302A1 (en) 1999-07-29
HUP0101739A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
ES2085582T3 (es) Composicion cosmetica capaz de difuminar los defectos de la piel.
NZ334387A (en) Cosmetic composition with hexanediol-behenyl beeswax, said composition being free of added fatty alcohol and castor oil wax
AR039379A1 (es) Matriz para la liberacion sostenida, invariable e independiente de compuestos activos
KR880007051A (ko) 틀니 안정용 조성물
EP0953335A1 (fr) Composition solide déodorante
DE69707669T2 (de) Orale pharmazeutische zusammensetzungen mit sexualhormonen
ES2192226T3 (es) Composicion farmaceutica oral que contiene agentes activos antimicrobianos y pantoprazol de liberacion prolongada.
KR880000738B1 (ko) 활성화합물 방출효과가 우수한 탄성액상 플라스터형의 항진균제 조성물의 제조방법
CO4970814A1 (es) Formulaciones de tiagabine de liberacion prolongada con efec tos secundarios reducidos
US10376450B2 (en) Anhydrous deodorant composition made from bicarbonate
KR102322440B1 (ko) 내수성이 있는 무스형의 화장료 조성물
EP0547897A2 (en) Cosmetic composition
CO4910117A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
ES2192045T3 (es) Formulacion cosmetica con volumen variable.
ITMI991747A1 (it) Dispositivo per erogazione spray di una composizione per applicazionetopica comprendente vitamina e e acidi grassi essenziali
CA2357520A1 (en) Absorbent article and barrier agent for absorbent article
ES2256237T3 (es) Vela de incenso.
KR100814035B1 (ko) 아데노신 베이스를 함유한 유분산 타입의 입술 주름 개선용화장료 조성물
AR009139A1 (es) Composiciones alimenticia solida formada por un relleno revestido por lo menos parcialmente con una capa protectora, barra alimenticia, barraalimenticia chocolatada, procedimiento para la preparacion de dicha composicion composicion cremosa, y utilizacion de un emulsionante hidrosoluble
KR102394107B1 (ko) 천연 유래 왁스를 포함하는 입술용 화장료 조성물 및 이의 제조 방법
RU2497506C2 (ru) Композиции для чрескожного введения
JP6158622B2 (ja) 油性棒状化粧料
JP2020520932A (ja) 二相化粧品組成物
US20220347300A1 (en) Light activated gasotransmitter generating compositions
AR016483A1 (es) Utilizacion de un agente para la prevencion de una enfermedad de las encias